SCHEMBL1301294

SCHEMBL1301294

COc1nc2c(cc1NCc1ccccc1Cl)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 1/20 0.51
▸ PDE9A O76083 2/20 0.39
▸ RXFP1 Q9HBX9 3/20 0.37
▸ POLB P06746 2/20 0.37
▸ TP53 P04637 2/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ PLA2G1B P04054 1/20 0.37
▸ ATG4B Q9Y4P1 1/20 0.37
▸ CD38 P28907 1/20 0.37
▸ PDE10A Q9Y233 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ASPH Q12797 1/20 0.35
▸ KDM8 Q8N371 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.33
▸ PDCD1 Q15116 1/20 0.33
▸ CD274 Q9NZQ7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1301301 1.00 METTL3 (0.51) METTL3PDE9ARXFP1POLBTP53
SCHEMBL1300614 0.94 METTL3 (0.51) METTL3PDE9ARXFP1POLBTP53
SCHEMBL1300617 0.94 METTL3 (0.51) METTL3PDE9ARXFP1POLBTP53
SCHEMBL1301788 0.92 METTL3 (0.59) METTL3RXFP1POLBTP53CD38
SCHEMBL1301791 0.92 METTL3 (0.59) METTL3RXFP1POLBTP53CD38
SCHEMBL1301276 0.90 METTL3 (0.47) METTL3RXFP1TP53MEN1KMT2A
SCHEMBL1301270 0.90 METTL3 (0.47) METTL3RXFP1TP53MEN1KMT2A
SCHEMBL1300646 0.89 METTL3 (0.44) METTL3PDE9ARXFP1POLBMEN1
SCHEMBL1300641 0.89 METTL3 (0.44) METTL3PDE9ARXFP1POLBMEN1
SCHEMBL1301244 0.89 METTL3 (0.44) METTL3MEN1KMT2ACD38ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 — — US disclosed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 — — US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885PDE9A 1229/4885RXFP1 4815/4885
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885PDE9A 1229/4885RXFP1 4815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback